Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)-Reference-Cited by-同舟云学术

Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5)

Published:2022-08 Issue: Volume:166 Page:S50-S51
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Li Ning,Zhu Jianqing,Yin Rutie,Wang Jing,Pan Lingya,Kong Beihua,Zheng Hong,Liu Jihong,Wu Xiaohua,Wang Li,Huang Yi,Wang Ke,Zou Dongling,Zhao Hongqin,Wang Chunyan,Lu Weiguo,Lin An,Lou Ge,Li Guiling,Qu Pengpeng,Yang Hongying,Zhen Xiaoa,Hang Wenzhao,Hou Jianmei,Wu Lingying

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination ofBRCAdeep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancer;2024-09-10

2. Prescribers and patients drive maintenance therapy patterns in a community oncology practice: National guidelines versus the real-world experience;Gynecologic Oncology Reports;2024-08

3. SEOM–GEICO clinical guideline on epithelial ovarian cancer (2023);Clinical and Translational Oncology;2024-07-15

4. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies;International Journal of Gynecologic Cancer;2024-03

5. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis;Expert Review of Anticancer Therapy;2024-01-04